Skip to main content
OpenTrials
Completed

NCT Number: NCT06636565

Comparison of Pulmonary Function, Exercise Capacity, and Physical Activity Level Between Children With Hemophilia and Healthy Controls

Hemophilia is a rare X-linked congenital bleeding disorder characterized by deficiency of clotting factor VIII (hemophilia A) or deficiency of factor IX (hemophilia B) with complex diagnosis and management. Participation in physical activity is still limited in children with hemophilia, probably due to protective attitudes of families/patients and avoidance of activity, and possibly also as a result of chronic pain. Exercise capacity has been identified as a protective factor against joint problems in hemophilia. Aerobic fitness is associated with better pulmonary function in children. Chronic pain and decreased range of motion due to recurrent bleeding in joints and muscles in hemophilia may indirectly affect posture and respiratory mechanics, leading to impaired pulmonary function. This study aims to compare pulmonary function, exercise capacity, posture, and physical activity level between children with hemophilia and healthy controls and to investigate the relationship between these parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemophilia Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Coagulation Protein Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Healthy Children Hematologic Diseases Hemic and Lymphatic Diseases Hemophilia A Hemorrhagic Disorders

Age range

8 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hacettepe University Faculty of Physical Therapy and Rehabilitation

Ankara, 06100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Hemophilia group

Inclusion criteria

  • Having been diagnosed with hemophilia and being clinically stable,
  • Being between the ages of 8-18,
  • Being on prophylaxis treatment (a routine treatment),
  • Being 125 cm or taller,
  • Being inhibitor negative at the time of enrollment,
  • To be able to cooperate with the tests to be performed,
  • Being willing to participate in the study.

Exclusion criteria

  • Being inhibitor positive at the time of enrollment,
  • Having a history of acute joint bleeding,
  • Being unable to bear weight on the extremities,
  • Having a history of acute intramuscular bleeding,
  • Having undergone radionuclide synovectomy,
  • Having a history of surgery on any of the lower extremity joints,
  • Having a severe cardiovascular, orthopedic or neurological problem that may affect the assessments.

Control group

Inclusion criteria

  • Not having any known internal or chronic disease
  • Being male between the ages of 8-18
  • Having full range of motion in the upper extremity
  • Having full range of motion in the lower extremity
  • Not having any history of injury or surgery in the lower extremity
  • Being 125 cm or taller
  • Being willing to participate in the study

Exclusion criteria

  • Having any problem that may affect the tests
  • Not having full range of motion in the upper extremity
  • Having a history of injury or surgery in any of the lower extremity joints
  • Having a neurological deficit
  • Having pain or movement limitation in the lower extremity

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. Forced vital capacity

    Time frame: 1st day

    Pulmonary function test using a spirometer will be performed. Forced vital capacity will be recorded.

  2. Forced expiratory volume in one second

    Time frame: 1st day

    Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second will be recorded.

  3. Forced expiratory volume in one second/forced vital capacity ratio

    Time frame: 1st day

    Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second/forced vital capacity ratio will be recorded.

  4. Peak expiratory flow

    Time frame: 1st day

    Pulmonary function test using a spirometer will be performed. Peak expiratory flow will be recorded. will be recorded.

  5. Forced mid-expiratory flow (FEF25-75)

    Time frame: 1st day

    Pulmonary function test using a spirometer will be performed. Forced mid-expiratory flow (FEF25-75) will be recorded. will be recorded.

  6. Hemophilia Joint Health Score

    Time frame: 1st day

    Hemophilia Joint Health Score is a scoring used by physiotherapists in hemophilia treatment centers to detect early hemophilic arthropathy symptoms and to monitor joint health. HJHS consists of edema (0-3), duration of edema (0-1), muscle atrophy (0-2), crepitus during movement (0-2), loss of flexion (0-3), loss of extension (0-3), joint pain (0-2) and evaluation of muscle strength of knees, ankles and elbows (0-4) and global gait score (0-4). The maximum score is 124, with higher scores indicating worse joint health.

  7. Corbin Posture Rating Scale

    Time frame: 1st day

    Corbin Posture Rating Scale and observational posture analysis. It is an assessment consisting of lateral and posterior posture analysis. '0' is excellent, 12 and above indicates poor posture.

  8. Exercise capacity

    Time frame: 1st day

    To assess exercise capacity, a symptom-limited cardiopulmonary exercise test will be performed on a bicycle ergometer using Godfrey protocol. Cardiopulmonary responses and effort perceptions will be recorded. In Godfrey protocol, workload increases are adjusted according to height: workload is increased by 10 W/min for < 125 cm, by 15 W/min for 125-150 cm and by 20 W/min for >150 cm.

  9. Physical activity level

    Time frame: 1st day

    The Physical Activity Questionnaire for Children (PAQ-C) and the Physical Activity Questionnaire for Adolescents (PAQ-A) will be used to assess physical activity levels. The Turkish versions of these assessment tools have been shown to be valid and reliable.

Sponsors and collaborators

Lead sponsor

Hacettepe University

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 10, 2024
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.